Rezivertinib
- Generic Name
- Rezivertinib
- Indication
用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的治疗。
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
Phase 3
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Target Recruit Count
- 270
- Registration Number
- NCT06955325
A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Beta Pharma, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04135820
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai, China
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Beta Pharma, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04135833
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beta Pharma Shanghai
- Target Recruit Count
- 369
- Registration Number
- NCT03866499
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Beta Pharma Shanghai
- Target Recruit Count
- 226
- Registration Number
- NCT03812809
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath